Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 6/20 | 0.40 |
| ▸ | PSMB1 | P20618 | 5/20 | 0.40 |
| ▸ | PSMB2 | P49721 | 5/20 | 0.40 |
| ▸ | LONP1 | P36776 | 5/20 | 0.40 |
| ▸ | PSMB11 | A5LHX3 | 4/20 | 0.40 |
| ▸ | PSMA7 | O14818 | 4/20 | 0.40 |
| ▸ | PSMA1 | P25786 | 4/20 | 0.40 |
| ▸ | PSMA2 | P25787 | 4/20 | 0.40 |
| ▸ | PSMA3 | P25788 | 4/20 | 0.40 |
| ▸ | PSMA4 | P25789 | 4/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 4/20 | 0.40 |
| ▸ | PSMB9 | P28065 | 4/20 | 0.40 |
| ▸ | PSMA5 | P28066 | 4/20 | 0.40 |
| ▸ | PSMB4 | P28070 | 4/20 | 0.40 |
| ▸ | PSMB6 | P28072 | 4/20 | 0.40 |
| ▸ | PSMB10 | P40306 | 4/20 | 0.40 |
| ▸ | PSMB3 | P49720 | 4/20 | 0.40 |
| ▸ | PSMA6 | P60900 | 4/20 | 0.40 |
| ▸ | PSMA8 | Q8TAA3 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7628056 | 0.83 | MMP8 (0.51) | PSMB5PSMB1PSMB2LONP1PSMB11 | |
| SCHEMBL6413367 | 0.81 | LMNA (0.40) | LMNAPSMB5PSMB1PSMB2LONP1 | |
| SCHEMBL8749847 | 0.80 | NAALAD2 (0.52) | LMNAMMP9MMP2MMP7 | |
| SCHEMBL7354243 | 0.80 | NAALAD2 (0.52) | LMNAMMP9MMP2MMP7 | |
| SCHEMBL7360690 | 0.79 | FCER2 (0.41) | LMNAMMP9MMP8MMP1MMP2 | |
| SCHEMBL6417248 | 0.79 | MMP1 (0.41) | LMNAMMP9MMP8MMP1MMP2 | |
| SCHEMBL6411770 | 0.78 | MMP1 (0.44) | LMNAPSMB5PSMB1PSMB2LONP1 | |
| SCHEMBL7363465 | 0.78 | LMNA (0.37) | LMNAPSMB5PSMB1PSMB2LONP1 | |
| SCHEMBL7360065 | 0.77 | MMP1 (0.51) | MMP9MMP8MMP1MMP2MMP3 | |
| SCHEMBL7365041 | 0.77 | MMP9 (0.55) | PSMB5PSMB1PSMB2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1272494-B1 | PHOTOCHROMIC SPIRO(INDOLINE)NAPHTHOXAZINES | YEDA RES & DEV (IL) | 2005-06-08 | — | — | EP | claimed |
| EP-0667770-B1 | INHIBITION OF TNF PRODUCTION | BRITISH BIOTECH PHARM (GB) | 1997-03-19 | — | — | EP | claimed |
| EP-0667770-A1 | INHIBITION OF TNF PRODUCTION. | BRITISH BIOTECH PHARM (GB) | 1995-08-23 | — | — | EP | claimed |
| WO-1994010990-A1 | INHIBITION OF TNF PRODUCTION | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1994-05-26 | — | — | WO | claimed |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2005-01-27 | — | — | US | disclosed |
| US-20040176393-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2004-09-09 | — | — | US | disclosed |
| EP-1366765-A1 | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing | WARNER-LAMBERT COMPANY LLC (US) | 2003-12-03 | — | — | EP | disclosed |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2002-04-25 | — | — | US | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |
| EP-0667770-B1 | INHIBITION OF TNF PRODUCTION | BRITISH BIOTECH PHARM (GB) | 1997-03-19 | — | — | EP | disclosed |
| EP-0667770-A1 | INHIBITION OF TNF PRODUCTION. | BRITISH BIOTECH PHARM (GB) | 1995-08-23 | — | — | EP | disclosed |
| WO-1994010990-A1 | INHIBITION OF TNF PRODUCTION | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1994-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176393-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | LMNA 1874/4885PSMB5 2044/4885PSMB1 2571/4885 |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | LMNA 1874/4885PSMB5 2044/4885PSMB1 2571/4885 |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | LMNA 1874/4885PSMB5 2044/4885PSMB1 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.